Veracyte [VCYT] vs Grail [GRAL] Detailed Stock Comparison
Veracyte
NASDAQ
Loading...
Grail
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Veracyte wins in 11 metrics, Grail wins in 6 metrics, with 0 ties. Veracyte appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Veracyte | Grail | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 56.29 | -0.52 | Grail |
| Price-to-Book Ratio | 1.55 | 0.48 | Grail |
| Debt-to-Equity Ratio | 4.23 | 2.67 | Grail |
| PEG Ratio | 59.10 | -0.01 | Grail |
| EV/EBITDA | 25.92 | -1.15 | Grail |
| Profit Margin (TTM) | 7.13% | -62.12% | Veracyte |
| Operating Margin (TTM) | 7.03% | -482.59% | Veracyte |
| EBITDA Margin (TTM) | 7.03% | N/A | N/A |
| Return on Equity | 2.86% | -62.22% | Veracyte |
| Return on Assets (TTM) | 1.94% | -11.98% | Veracyte |
| Free Cash Flow (TTM) | $63.81M | $-582.36M | Veracyte |
| 1-Year Return | 9.44% | 97.65% | Grail |
| Price-to-Sales Ratio (TTM) | 4.00 | 9.02 | Veracyte |
| Enterprise Value | $1.61B | $569.30M | Veracyte |
| EV/Revenue Ratio | 3.48 | 4.36 | Veracyte |
| Gross Profit Margin (TTM) | 69.46% | -62.60% | Veracyte |
| Revenue per Share (TTM) | $6 | $4 | Veracyte |
| Earnings per Share (Diluted) | $0.42 | $-59.59 | Veracyte |
| Beta (Stock Volatility) | 2.07 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Veracyte vs Grail Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Veracyte | 0.55% | -6.38% | -13.47% | -20.43% | -47.54% | -41.54% |
| Grail | -4.15% | -18.62% | -33.39% | 0.92% | 13.70% | 82.98% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Veracyte | 9.44% | -15.27% | -26.92% | 135.22% | 92.20% | 92.20% |
| Grail | 97.65% | 124.28% | 124.28% | 124.28% | 124.28% | 124.28% |
Performance & Financial Health Analysis: Veracyte vs Grail
| Metric | VCYT | GRAL |
|---|---|---|
| Market Information | ||
| Market Cap | $1.85B | $1.18B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 3,218,800 | 1,015,070 |
| 90 Day Avg. Volume | 1,752,003 | 1,255,653 |
| Last Close | $23.64 | $32.79 |
| 52 Week Range | $19.73 - $47.32 | $12.33 - $63.99 |
| % from 52W High | -50.04% | -48.76% |
| All-Time High | $86.03 (Feb 08, 2021) | $63.99 (Feb 17, 2025) |
| % from All-Time High | -72.52% | -48.76% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.18% | 0.19% |
| Quarterly Earnings Growth | 0.18% | 0.19% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | -0.62% |
| Operating Margin (TTM) | 0.07% | -4.83% |
| Return on Equity (TTM) | 0.03% | -0.62% |
| Debt to Equity (MRQ) | 4.23 | 2.67 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.26 | $68.38 |
| Cash per Share (MRQ) | $3.67 | $18.75 |
| Operating Cash Flow (TTM) | $89.42M | $-464,881,984 |
| Levered Free Cash Flow (TTM) | $76.93M | $-236,879,248 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Veracyte vs Grail
| Metric | VCYT | GRAL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 56.29 | -0.52 |
| Forward P/E | 59.10 | -2.51 |
| PEG Ratio | 59.10 | -0.01 |
| Price to Sales (TTM) | 4.00 | 9.02 |
| Price to Book (MRQ) | 1.55 | 0.48 |
| Market Capitalization | ||
| Market Capitalization | $1.85B | $1.18B |
| Enterprise Value | $1.61B | $569.30M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.48 | 4.36 |
| Enterprise to EBITDA | 25.92 | -1.15 |
| Risk & Other Metrics | ||
| Beta | 2.07 | N/A |
| Book Value per Share (MRQ) | $15.26 | $68.38 |
Financial Statements Comparison: Veracyte vs Grail
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VCYT | GRAL |
|---|---|---|
| Revenue/Sales | $114.47M | $31.84M |
| Cost of Goods Sold | $34.97M | $51.77M |
| Gross Profit | $79.51M | $-19.93M |
| Research & Development | $17.72M | $53.63M |
| Operating Income (EBIT) | $1.16M | $-153.61M |
| EBITDA | $3.03M | $-114.33M |
| Pre-Tax Income | $7.43M | $-146.41M |
| Income Tax | $381,000 | $-40.20M |
| Net Income (Profit) | $7.05M | $-106.21M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VCYT | GRAL |
|---|---|---|
| Cash & Equivalents | $186.12M | $133.90M |
| Total Current Assets | $383.15M | $727.66M |
| Total Current Liabilities | $75.13M | $74.98M |
| Long-Term Debt | $43.09M | $51.34M |
| Total Shareholders Equity | $1.19B | $2.41B |
| Retained Earnings | $-436.94M | $-9.91B |
| Property, Plant & Equipment | $70.15M | $126.94M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VCYT | GRAL |
|---|---|---|
| Operating Cash Flow | $18.76M | $-88.63M |
| Capital Expenditures | $-1.82M | $-62,000 |
| Free Cash Flow | $3.54M | $-95.07M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VCYT | GRAL |
|---|---|---|
| Shares Short | 6.11M | 5.52M |
| Short Ratio | 6.38 | 4.03 |
| Short % of Float | 0.09% | 0.18% |
| Average Daily Volume (10 Day) | 3,218,800 | 1,015,070 |
| Average Daily Volume (90 Day) | 1,752,003 | 1,255,653 |
| Shares Outstanding | 77.77M | 33.89M |
| Float Shares | 77.87M | 24.10M |
| % Held by Insiders | 0.01% | 0.14% |
| % Held by Institutions | 1.07% | 0.68% |
Dividend Analysis & Yield Comparison: Veracyte vs Grail
| Metric | VCYT | GRAL |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |